Symbiotec Pharmalab Stock Price Analysis and Quick Research Report. Is Symbiotec Pharmalab an attractive stock to invest in?

Stock investing requires careful analysis of financial data to determine a company's true net worth. This is generally done by examining the company's profit and loss account, balance sheet and cash flow statement, which can be time-consuming and cumbersome.

Examining a company's financial ratios is an easier way to determine its performance, which can help to make sense of the overwhelming amount of information in its financial statements. 

Here are a few indispensable ratios that should be a part of every investor’s research process, or, in simpler words, how to analyse Symbiotec Pharmalab. 

• PE ratio: Price to Earnings ratio, which indicates how much an investor is willing to pay for a share for every rupee of earnings. A general rule of thumb is that shares trading at a low P/E are undervalued (it depends on other factors too). Symbiotec Pharmalab has a PE ratio of 79.1125752223258 which is high and comparatively overvalued.

• Return on Assets (ROA): Return on Assets measures how effectively a company can earn a return on its investment in assets. In other words, ROA shows how efficiently a company can convert the money used to purchase assets into net income or profits. Symbiotec Pharmalab has ROA of 8.8843% which is a bad sign for future performance. (Higher values are always desirable.)

• Current ratio: The current ratio measures a company's ability to pay its short-term liabilities with its short-term assets. A higher current ratio is desirable so that the company could be stable to unexpected bumps in business and economy. Symbiotec Pharmalab has a Current ratio of 1.6684.

• Return on equity: ROE measures the ability of a firm to generate profits from its shareholders' investments in the company. In other words, the return on equity ratio shows how much profit each rupee of common stockholders’ equity generates. Symbiotec Pharmalab has a ROE of 12.4056%. (Higher is better)

• Debt to equity ratio: It is a good metric to check out the capital structure along with its performance. Symbiotec Pharmalab has a Debt to Equity ratio of 0.0679 which means that the company has low proportion of debt in its capital.

• Sales growth: Symbiotec Pharmalab has reported revenue growth of 19.5218% which is fair in relation to its growth and performance. 

• Operating Margin: This will tell you about the operational efficiency of the company. The operating margin of Symbiotec Pharmalab for the current financial year is 21.220056768922%.

• Dividend Yield: It tells us how much dividend we will receive in relation to the price of the stock. The current year dividend for Symbiotec Pharmalab is Rs 0 and the yield is 0%.

• Earnings Per Share: It tells us how much profit is allocated to to each outstanding share of a common stock. The latest EPS of Symbiotec Pharmalab is Rs 13.8423. The higher the EPS, the better it is for investors. 

One can find all the Financial Ratios of Symbiotec Pharmalab in Ticker for free. Also, one can get the intrinsic value of Symbiotec Pharmalab by using Valuation Calculators, which are available with a Finology ONE subscription. 

Symbiotec Pharmalab FAQs

Q1. What is Symbiotec Pharmalab share price today?
Ans: The current share price of Symbiotec Pharmalab is Rs 1095.1.

Q2. What is the market capitalisation of Symbiotec Pharmalab?
Ans: Symbiotec Pharmalab has a market capitalisation of Rs 7036.68682512 Cr., calculated based on its latest share price.

Q3. What are the P/E and P/B ratios of Symbiotec Pharmalab?
Ans: The PE ratio of Symbiotec Pharmalab is 79.1125752223258 and the P/B ratio of Symbiotec Pharmalab is 0, showing how the stock is valued against its earnings and book value.

Q4. What is the 52-week high and low of Symbiotec Pharmalab share?
Ans: The 52-week high share price of Symbiotec Pharmalab is Rs 1193.7, and the 52-week low share price of Symbiotec Pharmalab is Rs 934.2.

Q5. Does Symbiotec Pharmalab pay dividends?
Ans: Currently, Symbiotec Pharmalab does not pay dividends. Dividend yield of Symbiotec Pharmalab is around 0%.

Q6. What are the face value and book value of Symbiotec Pharmalab shares?
Ans: The face value of Symbiotec Pharmalab shares is Rs 2, while the book value per share of Symbiotec Pharmalab is around Rs 0. Face value is the nominal value set by the company, whereas book value reflects its accounting worth.

Q7. What is the debt of Symbiotec Pharmalab?
Ans: Symbiotec Pharmalab has a total debt of Rs 51.717 Cr., which affects investor sentiment and financial stability. 

Q8. What are the ROE and ROCE of Symbiotec Pharmalab?
Ans: The ROE of Symbiotec Pharmalab is 12.4056% and ROCE of Symbiotec Pharmalab is 15.7496%. ROE shows how efficiently the company is generating profit from shareholders’ equity, while the ROCE is reflects how efficiently the company uses its capital to generate returns.

Q9. Is Symbiotec Pharmalab a good buy for the long term?
Ans: The Symbiotec Pharmalab long-term outlook depends on debt levels, earnings growth, and sector trends. If it sustains profits and manages debt well, it may be considered for long-term investment.

Q10. Is Symbiotec Pharmalab undervalued or overvalued?
Ans: Based on valuation ratios like P/E, P/B, and EV/EBITDA, one can analyse whether the Symbiotec Pharmalab appears undervalued or overvalued at current levels. You can check detailed valuation metrics and peer comparisons on Finology Ticker.

Q11. How to check Symbiotec Pharmalab’s financials?
Ans: You can review Symbiotec Pharmalab’s financial statements - including balance sheet, income statement, and quarterly results - on Finology Ticker.